You are here

ASCO

As cancer drug shortages persist, ASCO official urges congressional action at hearing

Fierce Pharma

Fri, 02/9/24 - 11:16 am

Takeda's Iclusig shows potential to become standard of care in acute lymphoblastic leukemia subtype

Fierce Pharma

Wed, 02/15/23 - 06:16 pm

acute lymphoblastic leukemia

ASCO: Takeda Oncology ready to stoke partnerships to fire up cancer-fighting pillar technologies

Fierce Biotech

Thu, 06/9/22 - 11:00 am

Takeda Oncology

Gilead's Immunomedics settles over-hyped ASCO data mishap for $4M

Endpoints

Mon, 04/18/22 - 10:44 am

Gilead Sciences

AstraZeneca/Merck come out of ASCO GU with a big win over J&J in battle over prostate cancer franchises

Endpoints

Tue, 02/15/22 - 11:31 pm

prostate cancer

Pharmacist-driven biosimilar substitution saves money

GaBI

Sat, 08/28/21 - 09:08 pm

Include cancer patients in COVID-19 vaccine trials, say ASCO and Friends of Cancer Research

RAPS.org

Tue, 06/22/21 - 10:30 pm

clinical trials

ASCO-Friends meeting: NCI offers strategies to modernize cancer trials

RAPS.org

Tue, 04/13/21 - 10:07 pm

clinical trials

COVID-19 Pushes Cancer Conference Into a Virtual Format

Motley Fool

Wed, 03/25/20 - 10:47 am

Did cancer clinical trials stay on track at ASCO 2019?

Pharmaforum

Fri, 07/19/19 - 01:00 pm

clinical trials

prostate cancer

pancreatic cancer

Patient access pitfalls, regulatory inconsistencies hamper tissue agnostic drugs

BioCentury

Fri, 04/26/19 - 07:41 pm

drug development

clinical trials

tissue-agnostic drugs

The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials

Yahoo/Benzinga

Sun, 02/10/19 - 11:08 pm

Motif Biosciences

Aveo Pharmaceuticals

Calithera Biosciences

ASCO and Friends of Cancer Research Draft 5 Guidances for FDA

RAPS.org

Thu, 08/9/18 - 08:23 pm

clinical trials

Friends of Cancer Research

Is ASCO Sending Mixed Messages On Cancer Drug Value?

Forbes

Fri, 06/15/18 - 09:51 am

IDO Don’ts: After Immunotherapy Failure, Experts Say Slow Down

Xconomy

Thu, 05/31/18 - 08:17 pm

Does a Blue Ribbon Make This Biotech Stock a Buy Now?

Motley Fool

Sat, 05/19/18 - 11:18 am

Winners and Losers From the Biggest Cancer Meeting of the Year (So Far)

Motley Fool

Fri, 05/18/18 - 10:00 pm

Blueprint Medicines

Nektar Therapeutics

Jounce Therapeutics

Syndax is hit with a setback during the ASCO preview round as lead drug flops in mid-stage study

Endpoints

Fri, 05/18/18 - 12:17 pm

HDAC inhibitors

Additional Results from Phase I Study Show Inovio's INO-5150 Stabilizing Effect on Prostate Cancer

CP Wire

Fri, 05/18/18 - 09:57 am

prostate cancer

clinical trials

5 takeaways from the first look at cancer's biggest conference

Biopharma Dive

Thu, 05/17/18 - 10:44 pm

Bristol-Myers Squibb

Jounce Therapeutics

Pages